Search

Your search keyword '"Dienstmann, R."' showing total 118 results

Search Constraints

Start Over You searched for: Author "Dienstmann, R." Remove constraint Author: "Dienstmann, R." Publisher elsevier ltd Remove constraint Publisher: elsevier ltd
118 results on '"Dienstmann, R."'

Search Results

1. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group

3. ESMO Guidance for Reporting Oncology real-World evidence (GROW)

4. ESMO Guidance for Reporting Oncology real-World evidence (GROW)

6. Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer

7. Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network

8. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group

15. 43P MDM2 alterations in primary brain tumors: A potential niche for targeted therapy

18. 160P COLUMBIA-1: A phase Ib/II, open-label, randomized, multicenter study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab as first-line (1L) therapy in metastatic microsatellite-stable colorectal cancer (MSS-mCRC)

19. O-024 Circulating tumor DNA extended RAS mutational analysis as a surrogate of mutational status of tumor samples in metastatic colorectal cancer and its impact on patient selection for anti-EGFR therapy

22. 2193P Real-world evidence of the impact of immunotherapy (IT) on overall survival (OS) of patients (p) with malignant pleural mesothelioma (MPM) adjusted for tumor histology

23. 2144P The PRognostic Oncologic Plantology (PROP) website tool predicts 30-day mortality in hospitalized cancer patients on treatment

27. 503MO Real-world clinical and genomic characterization of gliomas: Predictive and prognostic insights

31. 702P Genomic alterations in epigenetic modifiers and response to epigenetic-targeted agents (ETAs) in patients (pts) with recurrent/metastatic (R/M) salivary gland tumours (SGTs)

32. 686P Next generation sequencing (NGS) helps predict response to immunotherapy (IO) in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)

33. 290P Potential enrichment strategies for next-generation sequencing (NGS) in primary brain cancers (pBCs) in a clinical series according to ESMO scale for clinical actionability of molecular targets (ESCAT)

40. 426P Spotlight on refractory metastatic colorectal cancer (refMCRC): Role of prognostic characteristics in the continuum of care

41. LBA-3 Integrated analysis of cell-free DNA (cfDNA) BRAF mutant allele fraction (MAF) and whole exome sequencing in BRAFV600E metastatic colorectal cancer (mCRC) treated with BRAF-antiEGFR +/- MEK inhibitors

44. 2O Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): Analysis of the GeparSixto randomized clinical trial

46. 35P Toxicity and safety of novel immuno-oncology (IO) treatments after prior immune checkpoint inhibitors (ICIs) exposure

50. 1545P DNA damage repair (DDR) gene mutations (mut) are predictors of response to platinum-based chemotherapy in advanced pancreatic cancer (PC) patients (pts)

Catalog

Books, media, physical & digital resources